<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03713216</url>
  </required_header>
  <id_info>
    <org_study_id>402</org_study_id>
    <nct_id>NCT03713216</nct_id>
  </id_info>
  <brief_title>Comparison of the Efficacy and Safety of NALDEBAIN With Conventional Treatment After Laparoscopic Cholecystectomy</brief_title>
  <official_title>Comparison of the Efficacy and Safety of NALDEBAIN With Conventional Treatment After Laparoscopic Cholecystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cathay General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cathay General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effect and safety of NALDEBAIN versus Morphine as needed in patients after
      laparoscopic cholecystectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-labeled, randomized clinical trial. Group A will receive one dose of
      NALDEBAIN before surgery. Group B will receive morphine as needed. Pain will be assessed for
      PACU, 4, 24, 48, 72 hours after surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Actual">January 1, 2020</completion_date>
  <primary_completion_date type="Actual">October 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative pain score</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>Using visual analog scale (VAS) with grades from 0 (no pain) to 10 (worst pain)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Consumption of supplemental analgesics</measure>
    <time_frame>From Day 0 to Day 3</time_frame>
    <description>Sum of supplemental analgesics</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of adverse event</measure>
    <time_frame>From Day 0 to Day 3</time_frame>
    <description>Times and incidence of adverse events (injection site reaction, vomiting, nausea, dizziness)</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Patient satisfaction</measure>
    <time_frame>Day 3</time_frame>
    <description>Percentage of patient satisfaction by 5-grade with 'highly satisfied', 'satisfied', 'uncertain', 'dissatisfied' or 'very dissatisfied'.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Naldebain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive one dose of Naldebain before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive morphine after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naldebain</intervention_name>
    <description>150 mg Nalbuphine sebacate</description>
    <arm_group_label>Naldebain</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Morphine</description>
    <arm_group_label>Morphine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female with 20 years old or older.

          2. Scheduled to electively undergo laparoscopic cholecystectomy.

          3. Ability and willingness to provide informed consent.

        Exclusion Criteria:

          1. Not willing to adhere to the study visit schedule and complete all study assessments.

          2. History of hypersensitivity or allergy to opioid, or NSAIDs or sesame oil.

          3. Any clinically significant condition that may interfere with study assessments or
             compliance.

          4. Pregnant or breastfeeding.

          5. Medical history may cause abnormal intracranial pressure.

          6. History of dependency, addiction, and withdrawal for narcotic drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sing-Ong Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cathay General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cathay General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 16, 2018</study_first_submitted>
  <study_first_submitted_qc>October 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2018</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

